Brain tumour therapy company GT Medical Technologies and Theragenics Corporation have teamed up to expand physician access to Cesium-131 seeds for brachytherapy, a type of internal radiotherapy.  

Under the agreement, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for a variety of non-brain cancer-related treatments, including prostate cancer. 

Cesium-131 is a common isotope used with low dose rate (LDR) brachytherapy, a radiation treatment where tiny radioactive seeds are implanted directly into or adjacent to a tumour. This approach delivers a high dose of radiation to cancer cells while minimising damage to surrounding healthy tissues. 

GT Medical Technologies inherited the radioactive Cesium-131 seeds when it acquired Perspective Therapeutics subsidiary Isoray Medical in December 2023. The company will continue to manufacture Cesium-131 while moving its focus to expanding the adoption of the company’s US Food and Drug Administration (FDA)-approved GammaTile therapy.  

The GammaTile therapy device, which features a bioresorbable collagen tile with embedded Cesium-131 seeds, is intended for treating patients with operable brain tumours to eliminate residual tumour cells. It is implanted in the head after surgery to delay regrowth by immediately delivering radiation to the site from which the tumour was removed. 

GT Medical’s CEO Per Langoe said: “We are very pleased to align with Theragenics, a global brachytherapy leader, to propel the field of cancer care forward. This partnership ensures continued access to Cesium-131 for clinicians and patients, addressing critical healthcare needs.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March 2022, Biobot Surgical and BEBIG Medical signed a memorandum of understanding to develop a robotic-guided high-dose-rate brachytherapy solution to treat prostate cancer patients. 

According to a report on GlobalData’s Pharma Intelligence Center, the prostate cancer market will generate $18.8bn globally in 2028. 

In July 2023, the FDA approved CivaTech Oncology’s polymer-encapsulated brachytherapy device. CivaDerm is applied similarly to a bandage to provide an LDR brachytherapy treatment option for patients with skin cancer.